Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03250338 · ClinicalTrials.gov registry record · Phase 3
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
A Phase 3 study, sponsored by Arog Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 106
- Enrollment target
NCT03250338 is a Phase 3 study that has completed, run by Arog Pharmaceuticals. The registered enrollment target is 106 participants.
The verdict
NCT03250338, a Phase 3 study, has completed, sponsored by Arog Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 106 participants
- Enrollment target
Study Summary
This is a randomized, multi-center, double-blind, placebo-controlled study designed to evaluate the efficacy of crenolanib administered following salvage chemotherapy, consolidation chemotherapy, post bone marrow transplantation and as maintenance in relapsed/refractory AML subjects with FLT3 activating mutation.
Interventions
- DRUG Fludarabine
- DRUG Cytarabine
- DRUG Mitoxantrone
- DRUG Placebo Oral Tablet
- DRUG Crenolanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2018-08-16 |
| Est. Completion | 2026-04-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03250338
The ClinicalTrials.gov registry entry for NCT03250338 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arog Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT03250338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03250338 about?
NCT03250338 is a clinical study titled "Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML". This is a randomized, multi-center, double-blind, placebo-controlled study designed to evaluate the efficacy of crenolanib administered following salvage chemotherapy, consolidation chemotherapy, post bone marrow transplantation and as maintenance in relapsed/refractory AML subjects with FLT3 activa...
What is the current status of trial NCT03250338?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 106 participants. The study started on 2018-08-16. Estimated completion is 2026-04-03.
What interventions are being tested in trial NCT03250338?
The interventions under investigation include: Fludarabine (DRUG), Cytarabine (DRUG), Mitoxantrone (DRUG), Placebo Oral Tablet (DRUG), Crenolanib (DRUG).
Who is sponsoring clinical trial NCT03250338?
This trial is sponsored by Arog Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.